Axsome Therapeutics (AXSM) Total Liabilities (2015 - 2026)

Axsome Therapeutics' Total Liabilities history runs 12 years deep, the most recent figure standing at $659.0 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 21.26% year-over-year to $659.0 million; the TTM figure through Mar 2026 stood at $659.0 million (up 21.26% YoY), while the FY2025 annual figure was $601.5 million, up 17.6% from the prior year.
• Total Liabilities came in at $659.0 million for Q1 2026 at Axsome Therapeutics, up from $601.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $659.0 million in Q1 2026 to a low of $73.9 million in Q1 2022.
• A 5-year average of $398.5 million and a median of $401.7 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities climbed 4.6% in 2022 and jumped 275.52% in 2023, its largest moves.
• Axsome Therapeutics' Total Liabilities stood at $221.9 million in 2022, then surged by 79.01% to $397.3 million in 2023, then climbed by 28.75% to $511.5 million in 2024, then climbed by 17.6% to $601.5 million in 2025, then advanced by 9.56% to $659.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $659.0 million, $601.5 million, and $595.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison